Form 4: Immunome CFO Max Rosett Executes Stock Option, Sells Shares to Cover
SEC Form 4
Immunome's Chief Financial Officer, Max Rosett, exercised stock options and sold shares to cover the transaction on September 19, 2024.
Summary
- On September 19, 2024, Max Rosett, the Chief Financial Officer of Immunome Inc., executed a stock option to acquire 42,000 shares at $1.05 per share.
- Following the exercise, Rosett sold 14,380 shares at a weighted average price of $16.01, with prices ranging from $15.97 to $16.10.
- After these transactions, Rosett directly owns 47,476 shares of Immunome Inc.
- Rosett also holds options to purchase 91,848 shares.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The sale of shares after exercising options is a common way for executives to realize compensation and manage their personal finances.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/24/2023 | 25% of the shares vested. |
| 10/12/2023 | Date of Reporting Person's Form 3 filing which contained a scrivener's error reflecting an exercise price of $1.06 instead of the correct exercise price of $1.05. |
| 09/19/2024 | Date of transaction: Rosett exercised stock options and sold shares. |
| 03/22/2033 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.